Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS005 in Moderate to Severe Chronic Plaque Psoriasis
NCT05975268Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of roconkibart in psoriasis (3 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Psoriasis Area and Severity Index 90 at 12 weeks and static Physician's Global Assessment at 12 weeks. Started Aug 2023; status: completed.
02
Drugs
roconkibart
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT05975268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05975268.